Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). The doses specified relate to the doses of PEG. Secondary objectives were measured by analysis of a subject diary and self-reported BM data. The secondary objectives included comparisons of PEG+E doses at 24 h for: BM control; relief of gas; relief of bloating; and relief of abdominal discomfort/cramping.

In addition, the proportion of subjects with a BM (without straining and without hard and/or lumpy stool) within the first 24 h of treatment for subjects taking different doses of PEG+E was evaluated for the time to first BM.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Cathartics; Laxatives; Polyethylene glycol 3350

Criteria

Inclusion Criteria:

• A willingness to participate in the study and comply with its procedures

• Must be ambulatory

• Male or female subjects aged 18 years or older who met two or more of the following modified Rome III-based criteria for constipation: (a) straining during at least 25% of defecations; (b) lumpy or hard stools in at least 25% of defecations; (c) sensation of incomplete evacuation for at least 25% of defecation; (d) sensation of anorectal obstruction/blockage for at least 25% of defecations; (e) manual maneuvers to facilitate at least 25% of defecations (eg, digital evacuation, support of the pelvic floor), and (f) fewer than 3 defecations per week

• Criteria fulfilled for the last 3 months with symptom onset at least 6 mo prior to diagnosis

• Had a self reported or documented history of chronic constipation

• Agreed not to use laxatives other than the study treatment from baseline/informed consent to end-of-study

• Agreed to maintain a similar diet from the week before Visit 3 to the end-of-study were to be enrolled

• Additionally required not to use any treatment known to cause constipation during the study (for subjects enrolled after Amendment 1)

• If a female subject, either surgically sterile, 2 years postmenopausal, or using an acceptable method of contraception. Abstinence was not an acceptable method of contraception. Females of childbearing potential had to have a urine pregnancy test (human chorionic gonadotropin [HCG]) that was negative at Visit 3

• Be able to read and write in the diaries in English

Exclusion Criteria:

• Had loose stools without the use of laxatives

• Recurrent abdominal pain

• Known or suspected bowel perforation, obstruction, or fecal impaction; or had gastric retention, inflammatory bowel disease, bowel resection, or colostomy

• Celiac disease or known gluten sensitivity

• Known renal or hepatic insufficiency

• Recent history of alcohol abuse or drug abuse

• History of psychiatric disorders

• History of significant ongoing medical problems or scheduled for surgical procedures

• Subjects who, in the opinion of the Investigator, should not have been included in the study for any reason, including inability to follow study procedures

• Participated in an investigational clinical, surgical, drug or device study within the past 30 days

• Pregnant or lactating

• Allergic to PEG or PEG+E

• Employed by or have immediate family members employed by a company that manufactures laxative products

• Participant or family member of the Investigator or site staff directly involved with this study